A new study published in Nature reveals that a person’s genetic makeup plays a critical role in how they respond to popular weight-loss medications like semaglutide and tirzepatide. By analyzing data from 27,885 patients, researchers identified specific genetic markers that determine both the efficacy of the drugs and the likelihood of experiencing side effects.
The findings offer a potential roadmap for precision medicine in obesity treatment. Currently, doctors prescribe these medications without knowing how an individual patient will react, often leading to varied results in weight loss and tolerability.
The role of GLP1R and GIPR variants
The study highlights a specific missense variant in the GLP1R gene, which is significantly associated with higher weight loss efficacy. Patients carrying this variant can expect to lose approximately 0.76 kilograms more per copy of the effect allele compared to those who do not.
Beyond efficacy, the research team linked genetic variations in both GLP1R and GIPR to common treatment-related side effects like nausea and vomiting. Notably, the study found that the GIPR association specifically affects patients using tirzepatide, a dual-action medication.
These genetic insights allow clinicians to stratify patients based on their predicted response and risk profiles. The researchers suggest that understanding these biological markers is a necessary step toward moving away from a 'one-size-fits-all' approach to obesity management.
As GLP-1 receptor agonists continue to see high prescription rates in the United States, these findings provide the first direct genetic evidence explaining why some patients reach their weight loss goals quickly while others struggle with adverse reactions. The study marks a shift toward tailoring weight-loss therapies to the individual patient's genetic profile.
